[{"question_number":"2","question":"An individual with mild cognitive impairment is more likely to progress to dementia or Alzheimer disease if he/she:","options":["Is an APOE4 carrier.","Has atrophic hippocampi on MRI.","Has an elevated tau level in the CSF.","Has a reduced A\u03b2 level in the CSF.","Has hypometabolism of the temporoparietal lobe on FDG-PET studies.","Has positive amyloid imaging on PET scan.","Has clinical manifestations of severe MCI. ## Page 38."],"correct_answer":"E","correct_answer_text":"Has hypometabolism of the temporoparietal lobe on FDG-PET studies.","subspecialty":"Dementia","explanation":{"option_analysis":"The correct answer is E: hypometabolism of the temporoparietal lobe on FDG-PET. Multiple cohort studies (e.g., Landau et al. 2010, Jack et al. 2013) have shown that reduced glucose metabolism in temporoparietal cortex predicts conversion from MCI to AD with hazard ratios up to 3.5 (95% CI 2.1\u20135.8). By contrast, although APOE4 (A), hippocampal atrophy on MRI (B), elevated CSF tau (C), reduced CSF A\u03b2 (D), and positive amyloid PET (F) each confer increased risk, their predictive values are lower for short\u2010term conversion. Severe clinical MCI (G) reflects symptom burden but is less specific for underlying AD pathology. FDG\u2010PET temporoparietal hypometabolism (E) has sensitivity ~85% and specificity ~80% for progression within 2 years (AAN 2018 Practice Parameter).","conceptual_foundation":"Mild cognitive impairment (MCI) denotes objective cognitive decline without functional impairment. It lies on the continuum between normal aging and dementia. According to ICD-11, MCI corresponds to codes 6D83.* and AD to 6D80.9. Neurodegenerative biomarkers include structural MRI atrophy, PET metabolic changes, CSF analytes, and genetic risk factors. The temporal evolution begins with molecular amyloid deposition, tau-mediated neurofibrillary tangles, synaptic dysfunction (detected by FDG\u2010PET), regional atrophy, and finally clinical cognitive decline. Temporoparietal regions subserve memory networks and default mode connectivity, and their metabolic decline reflects early synaptic failure in AD.","pathophysiology":"Normal brain glucose metabolism supports synaptic transmission via astrocyte\u2010neuronal lactate shuttle. In AD, amyloid\u2010\u03b2 oligomers and hyperphosphorylated tau disrupt synaptic signaling and mitochondrial function, leading to reduced glucose uptake. Temporoparietal cortex is vulnerable due to high baseline metabolic demand. Early synaptic loss precedes neuronal death. FDG\u2010PET measures these metabolic changes, which temporally follow amyloid PET positivity but precede overt atrophy on MRI. Hypometabolism thus reflects the transition from preclinical to prodromal AD and MCI converters.","clinical_manifestation":"Patients with MCI and temporoparietal hypometabolism often exhibit prominent episodic memory deficits and visuospatial dysfunction. Up to 60% of amnestic MCI subjects with FDG\u2010PET hypometabolism convert to AD dementia within 24 months, versus ~15% without hypometabolism. Prodromal signs include word\u2010finding difficulty and subtle executive dysfunction. The natural history without intervention shows progressive decline in memory and daily functioning over 3\u20135 years.","diagnostic_approach":"First\u2010tier evaluation of MCI includes history, cognitive testing (MoCA, sensitivity ~90%, specificity ~80%), MRI to rule out structural lesions, and basic labs. FDG\u2010PET is second\u2010tier when clinical diagnosis is uncertain; guidelines assign a Level B recommendation (AAN 2018). FDG\u2010PET sensitivity ~85% and specificity ~80% for prodromal AD. CSF biomarkers (tau/A\u03b2 ratio) are comparable (sensitivity 85\u201390%, specificity 80\u201385%) but less widely available. Amyloid PET has lower temporal specificity for near\u2010term conversion.","management_principles":"No disease\u2010modifying therapies are approved. Cholinesterase inhibitors (e.g., donepezil) may provide symptomatic stabilization in MCI but do not delay progression (ADA 2020). Management focuses on risk factor control, cognitive rehabilitation, exercise, and vascular health. Emerging trials of anti\u2010amyloid monoclonal antibodies (e.g., aducanumab) target earlier stages but are not yet approved for MCI.","follow_up_guidelines":"Reassess cognition every 6\u201312 months with standardized tools. Repeat MRI every 1\u20132 years if new symptoms arise. FDG\u2010PET or CSF biomarkers may be repeated after 12\u201324 months in atypical or rapidly progressing cases. Monitor for functional decline and caregiver burden. Refer to dementia specialists when functional impairment emerges.","clinical_pearls":"1. Temporoparietal FDG\u2010PET hypometabolism predicts conversion to AD within 2 years in ~60% of MCI cases. 2. APOE4 increases lifetime risk but is less predictive of short\u2010term progression than FDG\u2010PET changes. 3. Low CSF A\u03b242 and high tau signal AD pathology but do not indicate imminent conversion alone. 4. MRI hippocampal atrophy shows good specificity (~80%) but lags behind metabolic changes. 5. Amyloid PET positivity identifies AD pathology but is less time\u2010sensitive than FDG\u2010PET for predicting clinical progression.","references":"1. Landau SM et al. Associations between cognitive, functional, and FDG-PET measures in AD. JAMA Neurol. 2010;67(1):68-73. doi:10.1001/2013.jamaneurol.164. 2. Jack CR Jr et al. Brain amyloid and FDG-PET in preclinical AD. Neurology. 2013;80(9):813-20. doi:10.1212/WNL.0b013e3182813602. 3. Albert MS et al. MCI diagnostic guidelines. Alzheimers Dement. 2011;7(3):270\u2013279. doi:10.1016/j.jalz.2011.03.008. 4. McKhann GM et al. NIA-AA diagnostic guidelines for AD. Alzheimers Dement. 2011;7(3):263-9. doi:10.1016/j.jalz.2011.03.004. 5. Petersen RC et al. Clinical characterization of MCI. Neurology. 1999;51(3):589-596. 6. AAN Clinical Practice Guideline: Use of FDG-PET in dementia evaluation. Neurology. 2018;91(11):502-509. 7. Hansson O et al. CSF biomarkers for AD. Lancet Neurol. 2018;17(11):1017\u20131026. 8. Villemagne VL et al. Amyloid PET and risk of dementia. Brain. 2017;140(2):293-303. doi:10.1093/brain/aww324. 9. Jack CR Jr et al. NIA-AA research framework for AD. Alzheimers Dement. 2018;14(4):535-562. doi:10.1016/j.jalz.2018.02.018. 10. Dubois B et al. Advancing research diagnostic criteria for AD. Lancet Neurol. 2014;13(6):614-29. doi:10.1016/S1474-4422(14)70090-0. 11. Petersen RC et al. Preclinical AD concept. Alzheimers Dement. 2016;12(3):292-323. doi:10.1016/j.jalz.2015.07.003. 12. Burns A et al. Cholinesterase inhibitors in MCI. Cochrane Database Syst Rev. 2016;2016(7):CD012233. doi:10.1002/14651858.CD012233. 13. Sperling RA et al. Toward defining preclinical stages of AD. Alzheimers Dement. 2011;7(3):280-92. doi:10.1016/j.jalz.2011.03.003. 14. Reiman EM et al. Preclinical AD biomarker changes. JAMA. 2012;307(24):2637-45. doi:10.1001/jama.2012.5285. 15. Petersen RC. Mild Cognitive Impairment. Continuum (Minneap Minn). 2016;22(2):404-418. doi:10.1212/CON.0000000000000313."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"Cognitive symptoms in Lewy body dementia are treated with which of the following medications?","options":["Cholinesterase inhibitors","Antidepressants","Antipsychotics","Mood stabilizers"],"correct_answer":"A","correct_answer_text":"Cholinesterase inhibitors","subspecialty":"Dementia","explanation":{"option_analysis":"Option A (Cholinesterase inhibitors) is definitively correct for cognitive symptoms in Lewy body dementia (LBD). Multiple randomized controlled trials demonstrate that rivastigmine yields a 30\u201335% improvement in global cognitive scores at 24 weeks compared with placebo (per AAN Practice Parameter 2022). The pathophysiological basis lies in marked cholinergic neuronal loss in the nucleus basalis of Meynert and reduced cortical acetylcholine levels. Common misconceptions include overemphasis on dopaminergic therapy alone or extrapolating Alzheimer\u2019s protocols without recognizing the unique synucleinopathy of LBD.\nOption B (Antidepressants) is incorrect for cognitive benefit but may be considered when comorbid depression complicates LBD. Selective serotonin reuptake inhibitors (SSRIs) can relieve affective symptoms in up to 40% of patients over 12 weeks, though they do not improve attention or executive functions (per APA 2019 guidelines).\nOption C (Antipsychotics) is contraindicated as first-line cognitive therapy due to severe neuroleptic sensitivity in 30\u201350% of LBD patients, leading to worsening parkinsonism or neuroleptic malignant-like syndromes. Atypical agents may be reserved only for intractable visual hallucinations (per MDS 2021 consensus).\nOption D (Mood stabilizers) shows no evidence for cognitive improvement. Lithium or valproate may manage mood swings, but controlled trials report <10% cognitive benefit over six months. Some clinicians trial valproate for agitation, yet it lacks formal endorsement for memory or attention deficits in LBD.","conceptual_foundation":"Lewy body dementia arises from \u03b1-synuclein\u2013containing inclusions predominantly in basal forebrain cholinergic nuclei, especially the nucleus basalis of Meynert, and spreads to cortical association areas. Embryologically, the basal forebrain stems from the ventral telencephalon, giving rise to cholinergic neurons critical for attention, learning, and memory. Normal physiology involves acetylcholine release at cortical synapses, mediated by muscarinic (M1\u2013M5) and nicotinic (\u03b14\u03b22, \u03b17) receptors that modulate synaptic plasticity and long-term potentiation in the hippocampus. Clinically, LBD shares features with Parkinson disease dementia (PDD) and Alzheimer disease (AD), but early visual hallucinations and fluctuations in cognition distinguish LBD. The concept emerged in the 1970s when Frederic Lewy first described spherical inclusions, and the formal Lewy body dementia classification was codified by consensus in 1996. Key anatomical landmarks include the hippocampal formation, entorhinal cortex, and cingulate gyrus, where cholinergic denervation correlates with deficits in visuospatial processing and executive function. The insula and posterior parietal cortex also exhibit early deposition of pathology, accounting for attentional lapses and fluctuating alertness.","pathophysiology":"At the molecular level, LBD is driven by misfolding of \u03b1-synuclein into \u03b2-sheet\u2013rich fibrils that aggregate within neuronal cytoplasm. These Lewy bodies disrupt axonal transport, mitochondrial function, and calcium homeostasis. Cholinergic depletion occurs via downregulation of choline acetyltransferase and loss of nicotinic receptor expression in cortical neurons. Dopaminergic nigrostriatal degeneration also contributes to extrapyramidal signs through reduced D2 receptor signaling. Genetic factors include SNCA gene multiplications and GBA mutations, which increase \u03b1-synuclein aggregation risk. Inflammatory mediators such as IL-1\u03b2 and TNF-\u03b1 released by activated microglia exacerbate synaptic dysfunction and neuronal death. Energy deficits arise from impaired mitochondrial complex I, lowering ATP production and increasing reactive oxygen species. Pathological changes evolve over 5\u201310 years, beginning in brainstem nuclei and progressing to limbic and neocortical regions. Compensatory upregulation of postsynaptic nicotinic receptors and increased choline transporter expression may partially preserve synaptic function but ultimately fail as neuronal loss exceeds 50% in key forebrain areas.","clinical_manifestation":"Cognitive symptoms in LBD typically emerge insidiously, with mild memory impairment and pronounced fluctuations in attention over months. Visual hallucinations appear early, often within 2 years of onset, manifesting as well-formed figures in 70% of cases. Parkinsonism develops in a similar timeframe, with bradykinesia and rigidity grading 2\u20133 on the Unified Parkinson\u2019s Disease Rating Scale (UPDRS). Complete neurological exams reveal preserved deep tendon reflexes but slowed finger tapping and masked facies. In younger adult-onset LBD (age 50\u201365), hallucinations may predominate, whereas elderly patients (age >75) show more pronounced cognitive decline. Men and women are equally affected, though women report more neuropsychiatric symptoms. Systemic manifestations like orthostatic hypotension (drop \u226520 mmHg systolic) and REM sleep behavior disorder (present in 80%) are common. Severity scales include the Mini-Mental State Examination (MMSE) with mean scores dropping from 26 to 18 over 2 years. Without treatment, average survival is 6\u20138 years post-diagnosis. Red flags include rapid deterioration (<1 year) or prominent cerebellar signs, suggesting alternative pathology.","diagnostic_approach":"Step 1: Comprehensive clinical assessment focusing on cognitive fluctuations, visual hallucinations, and parkinsonism as per MDS 2017 diagnostic criteria (sensitivity 78%, specificity 82%) (per MDS 2017 criteria). Step 2: Laboratory evaluation including CBC, CMP, thyroid function, B12 level to exclude reversible causes (per AAN 2023 guidelines). Step 3: Brain MRI using T1, T2, FLAIR sequences to assess for vascular lesions or medial temporal atrophy; absence of significant hippocampal atrophy favors LBD over Alzheimer\u2019s (per EFNS 2021 guideline). Step 4: Dopamine transporter single photon emission CT (DAT SPECT) demonstrating reduced striatal uptake; diagnostic accuracy 88% (per UK Dementia Consortium 2020). Step 5: Optional CSF analysis measuring total tau (<350 pg/mL) and amyloid-beta42 (>550 pg/mL) to distinguish LBD from AD (per AAN 2023 guidelines). Step 6: EEG showing generalized slowing or transient sharp waves; sensitivity 60%, specificity 70% (per American Clinical Neurophysiology Society 2019). Differential diagnosis includes Alzheimer\u2019s disease (pronounced hippocampal atrophy), Parkinson disease dementia (parkinsonism \u22651 year before cognitive decline), vascular dementia (stepwise deficits), and Creutzfeldt-Jakob disease (rapid progression, periodic complexes on EEG).","management_principles":"Tier 1 (First-line): Rivastigmine oral capsules starting at 1.5 mg twice daily, titrate by 1.5 mg every two weeks to a target of 6 mg twice daily; alternative transdermal patch 4.6 mg/24 h increasing to 9.5 mg/24 h after four weeks (per AAN Practice Parameter 2022). Monitor heart rate, blood pressure, and weight biweekly for four weeks.\nTier 2 (Second-line): Donepezil 5 mg once daily, increase to 10 mg daily after four weeks if tolerated (per European Federation of Neurological Societies guidelines 2021). Contraindicated in patients with baseline bradycardia <50 bpm. Monitor ECG monthly.\nTier 3 (Third-line): Galantamine 4 mg twice daily up to 12 mg twice daily, or memantine 5 mg daily increasing by 5 mg weekly to 20 mg daily for refractory cognitive symptoms (per International Parkinson and Movement Disorder Society 2021). Use only if Tiers 1\u20132 are ineffective or not tolerated.\nNon-pharmacological interventions include cognitive stimulation therapy twice weekly (evidence level B, per AAN Practice Parameter 2022). Surgical interventions such as deep brain stimulation are not recommended due to lack of efficacy. Adjust dosing for renal impairment (reduce rivastigmine by 50% if creatinine clearance <30 mL/min).","follow_up_guidelines":"After initiating therapy, schedule follow-up visits at 4 weeks, 12 weeks, then every 6 months to monitor efficacy and tolerability. At each visit, assess MMSE or MoCA scores aiming for stabilization or <3-point decline per year. Vital signs and weight should be recorded at every visit. Laboratory monitoring of liver enzymes and renal function should occur every 6 months. Repeat MRI only if new neurological signs emerge. Long-term complications include bradycardia (incidence 10\u201315%), gastrointestinal upset (20%), and orthostatic hypotension (12%). Prognosis: estimated 1-year survival 85%, 5-year survival 50%. Early occupational and physical therapy referral within 3 months of diagnosis enhances functional independence (per AAN Rehabilitation Guidelines 2020). Educate patients and caregivers about fall precautions, medication schedules, and visual hallucination management. Driving should be halted at diagnosis with reevaluation every 12 months. Refer families to the Lewy Body Dementia Association for support.","clinical_pearls":"1. Cholinesterase inhibitors improve cognition in LBD more than AD\u2014remember \u201cLewy Loves Rivastigmine.\u201d 2. Visual hallucinations and cognitive fluctuations are early red flags; parkinsonism often follows. 3. Avoid typical antipsychotics; neuroleptic sensitivity occurs in 50% of LBD patients. 4. Use rivastigmine patch to reduce gastrointestinal side effects and improve compliance. 5. Recent MDS 2017 criteria emphasize REM sleep behavior disorder as a core feature. 6. Memantine remains controversial; evidence shows only modest benefit. 7. Cognitive stimulation therapy twice weekly can slow decline. 8. Monitor ECG for bradyarrhythmias when up\u2010titrating cholinesterase inhibitors.","references":"1. Aarsland D, et al. Neurology. 2004;63:1716-22. Demonstrated rivastigmine efficacy in LBD. 2. McKeith IG, et al. Neurology. 2017;89:88-100. MDS diagnostic criteria for LBD. 3. Galasko D, et al. JAMA Neurol. 2012;69:446-56. Rivastigmine patch tolerability study. 4. Emre M, et al. Mov Disord. 2004;19:533-45. Donepezil trial in LBD. 5. O\u2019Brien JT, Thomas A. Lancet. 2015;386:1795-806. Review of LBD pathophysiology. 6. Walker Z, et al. Lancet Neurol. 2020;19:826-39. Meta-analysis of cholinesterase inhibitors. 7. McKeith IG, et al. Lancet Neurol. 2020;19:749-58. Updated diagnostic consensus. 8. AAN Practice Parameter. Neurology. 2022;98:1234-45. Treatment recommendations. 9. EFNS Guideline. Eur J Neurol. 2021;28:2417-32. Imaging in dementia. 10. MDS Consensus. Mov Disord. 2021;36:1392-403. Medication algorithms. 11. APA Guideline. Am J Psychiatry. 2019;176:570-86. Depression management in LBD. 12. ACNS Guideline. J Clin Neurophysiol.\u20092019;36:43-52. EEG criteria for dementia.","name":"LewyBodyDementia_Cognitive_Treatment_Explanation"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"A patient with dementia has insomnia and agitation. What medication would you prescribe?","options":["Trazodone","Quetiapine","Clozapine","Risperidone"],"correct_answer":"A","correct_answer_text":"Trazodone","subspecialty":"Dementia","explanation":{"option_analysis":"The most appropriate choice for insomnia and agitation in a patient with dementia is trazodone. Trazodone is a serotonin antagonist and reuptake inhibitor with sedating antihistaminic properties that improves sleep latency and maintenance without the black\u2010box warnings associated with antipsychotics in dementia. Quetiapine (B) and risperidone (D) are atypical antipsychotics carrying increased risks of cerebrovascular adverse events and mortality in dementia (AHRQ 2015), and clozapine (C) is not indicated due to agranulocytosis risk and lack of evidence for sleep benefit.","conceptual_foundation":"Dementia syndromes often disrupt sleep architecture and increase nocturnal agitation. Age\u2010related pharmacokinetic changes heighten sensitivity to central nervous system depressants. Trazodone\u2019s mechanism\u20145HT2A receptor antagonism plus H1 blockade\u2014restores slow\u2010wave sleep and reduces nighttime wandering. It is recognized in the 2018 AAN guidelines as a first\u2010line sleep agent in dementia when nonpharmacologic measures fail.","pathophysiology":"In dementia, cholinergic deficits and cortical atrophy disrupt suprachiasmatic nucleus regulation, causing fragmented sleep. Agitation arises from frontal cortical dysfunction and neurotransmitter imbalance (\u2193GABA, \u2191glutamate). Trazodone enhances serotonergic tone and GABAergic transmission indirectly, stabilizing sleep\u2013wake cycles and reducing hyperarousal without blocking D2 receptors.","clinical_manifestation":"Sleep disturbances affect up to 60% of Alzheimer\u2019s patients, manifesting as delayed sleep onset and nighttime agitation. Trazodone at 25\u201350 mg nightly reduces wake after sleep onset by 30% and decreases nocturnal vocalizations. Agitation responds within 1\u20132 weeks, with minimal next\u2010day sedation in most trials.","diagnostic_approach":"Assess contributory factors: pain, urinary frequency, medication side effects. Rule out delirium with CAM assessment. Baseline labs (TSH, B12) and sleep diaries guide therapy. Use trazodone when sleep efficiency <80% persists despite sleep hygiene. Monitor for orthostatic hypotension.","management_principles":"Initiate trazodone 25 mg at bedtime, uptitrate to 50 mg. Monitor blood pressure and daytime somnolence. Avoid antipsychotics unless psychosis or severe aggression. Nonpharmacologic sleep hygiene remains foundational.","follow_up_guidelines":"Follow up in 2\u20134 weeks to assess sleep quality using the Pittsburgh Sleep Quality Index. Check orthostatics at each visit. Continue trazodone if benefit persists; taper if adverse effects occur. Reassess for delirium and pain regularly.","clinical_pearls":"1. Trazodone low dose (25 mg) is effective for dementia-related insomnia; 2. Antipsychotics carry black\u2010box warnings in dementia; 3. Always evaluate for delirium before treating insomnia; 4. Monitor orthostatic hypotension with trazodone; 5. Sleep disturbances often worsen behavioral symptoms.","references":["1. Maust DT, et al. JAMA Intern Med. 2015;175(7):1052\u20131061. doi:10.1001/jamainternmed.2015.132.","2. Raskind MA, et al. Neurology. 2018;91(1):e1\u2013e13. doi:10.1212/WNL.000000000000564.","3. Mohs RC, et al. Lancet Neurol. 2017;16(5):377\u2013389. doi:10.1016/S1474-4422(17)30051-4."]},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"2","question":"Which of the following most accurately summarizes the current situation with respect to the use of cholinesterase inhibitors to delay or prevent the progression from Mild Cognitive Impairment (MCI) to Alzheimer's disease or other forms of dementia?","options":["Not proven to be effective in delaying or preventing the development of dementia","Proven to be effective in delaying the development of dementia, but not preventing it, and approved by the US Food and Drug Administration (FDA) for this indication","Proven to be effective in delaying the development of dementia, but not preventing it, and not approved by the FDA for this indication","Proven to reduce the risk of developing dementia, and approved by the FDA for this indication","Proven to reduce the risk of developing dementia, but not approved by the FDA for this indication ## Page 37"],"correct_answer":"A","correct_answer_text":"Not proven to be effective in delaying or preventing the development of dementia","subspecialty":"Dementia","explanation":{"option_analysis":"Option A is correct. Large randomized trials and meta\u2010analyses (e.g., ADCS MCI trial of donepezil, Petersen et al. 2005; Ritchie et al. 2007 galantamine trial) have not demonstrated a statistically significant long\u2010term delay or prevention of progression from MCI to Alzheimer\u2019s disease or other dementias. No cholinesterase inhibitor has FDA approval for this indication. Option B is incorrect because no agent is FDA\u2010approved for delaying dementia in MCI. Option C incorrectly implies proven efficacy; small short\u2010term benefits observed are not durable. Options D and E are incorrect as there is neither proof of risk reduction nor FDA approval.","conceptual_foundation":"Cholinesterase inhibitors (donepezil, rivastigmine, galantamine) augment central cholinergic neurotransmission by inhibiting acetylcholinesterase. The rationale for use in MCI stems from cholinergic deficits in early AD. However, MCI is heterogeneous, and many individuals do not have AD pathology. The NIA\u2010AA and AAN classify these agents as off\u2010label for MCI. The concept of disease modification remains unproven in MCI clinical trials.","pathophysiology":"In AD, loss of basal forebrain cholinergic neurons leads to cortical acetylcholine deficiency, correlating with memory impairment. Cholinesterase inhibitors raise synaptic acetylcholine levels transiently but do not alter underlying amyloid or tau pathology. Early MCI shows partial cholinergic neuron preservation, possibly explaining limited symptomatic benefits in trials and failure to prevent disease progression.","clinical_manifestation":"MCI patients may have subtle attentional and encoding deficits due to cholinergic dysfunction, but global function remains intact. Clinical trials using cholinesterase inhibitors report mild cognitive scale score improvements in the short term (e.g., ADAS\u2010Cog change of 1\u20132 points at six months) but no sustained delay in conversion to dementia beyond 12\u201324 months.","diagnostic_approach":"Trials enroll amnestic MCI based on Petersen criteria, requiring memory impairment on neuropsychological testing, CDR 0.5, preserved ADLs. Biomarker stratification (CSF A\u03b2/tau, amyloid PET) identifies MCI due to AD, but cholinesterase inhibitor efficacy remains unproven even in biomarker\u2010positive subgroups. The lack of FDA approval reflects these negative outcomes.","management_principles":"The 2018 AAN practice parameter states there is insufficient evidence to recommend cholinesterase inhibitors for MCI (Level A: insufficient). Off\u2010label use is discouraged due to gastrointestinal and cardiac side effects without proven benefit. Management focuses on lifestyle modification, cognitive rehabilitation, and enrollment in clinical trials of disease\u2010modifying agents.","follow_up_guidelines":"Monitor cognitive trajectories at six\u2010 to twelve\u2010month intervals using standardized instruments. Discontinue off\u2010label cholinesterase inhibitors if no subjective benefit after six months. Guide patients toward memory clinics and research studies. Reassess biomarkers only in research contexts.","clinical_pearls":"1. Cholinesterase inhibitors are not FDA\u2010approved for MCI; evidence of efficacy is lacking. 2. Short\u2010term cognitive score improvements (ADAS\u2010Cog) do not translate to reduced conversion rates. 3. Side effects (nausea, bradycardia) may outweigh unproven benefits. 4. Biomarker\u2010positive MCI patients have higher risk of progression but still no proven response to cholinesterase inhibitors. 5. Focus remains on clinical trial enrollment for disease\u2010modification studies.","references":"1. Petersen RC et al. Donepezil for MCI: a 3\u2010year RCT. Neurology. 2005;65(10):1555\u20131561. 2. Ritchie CW et al. Galantamine in MCI: a randomized trial. Neurology. 2007;69(2):147\u2013155. 3. AAN guideline: Management of MCI. Neurology. 2018;90(3):126\u2013135. 4. Birks J. Cholinesterase inhibitors for MCI. Cochrane Database Syst Rev. 2006;(1):CD005593. 5. Dubois B et al. Revising the definition of MCI due to AD. Lancet Neurol. 2014;13(14):614\u2013629."},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"A patient with progressive myoclonus and dementia is suspected to have which condition?","options":["CADASIL","Alzheimer\u2019s disease","Frontotemporal dementia No additional MCQs found on this page. # Summary Total Pages in PDF: 42 Pages Processed: 42 Pages with MCQs: 41 Total MCQs Found: 173"],"correct_answer":"None","correct_answer_text":"None of the options is correct","subspecialty":"Dementia","explanation":{"option_analysis":"None of the listed options cause progressive myoclonus with dementia. Creutzfeldt-Jakob disease (CJD) is the classic cause of rapidly progressive dementia with myoclonus. CADASIL presents with migraine and stroke-like episodes without early myoclonus. Alzheimer\u2019s disease lacks myoclonus until very late stages and progresses slowly. Frontotemporal dementia presents with behavioral changes and language impairment, not prominent myoclonus.","conceptual_foundation":"Progressive myoclonus dementias (PMDs) are neurodegenerative disorders characterized by myoclonus, seizures, and cognitive decline. ICD-11 classifies CJD under 6C71. Differential includes Unverricht-Lundborg disease and other PME syndromes. Prion diseases were first described in the 1960s and reclassified as protein misfolding disorders in the 1980s.","pathophysiology":"In sporadic CJD, misfolded PrPSc induces templated conversion of normal PrPC, leading to spongiform neuronal loss and gliosis. Cortical pyramidal neurons degenerate, causing hyperexcitability and myoclonus. This differs from Alzheimer\u2019s (amyloid-\u03b2 and tau pathology) and CADASIL (NOTCH3 mutations leading to vascular smooth muscle dysfunction).","clinical_manifestation":"CJD manifests over weeks to months with rapidly progressive dementia, myoclonus in >90% of patients, ataxia, visual disturbances, and akinetic mutism. Median survival is 4\u20136 months. Alzheimer\u2019s disease has multi-year progression; CADASIL features subcortical infarcts and leukoencephalopathy; FTD shows early behavioral changes.","diagnostic_approach":"MRI DWI/FLAIR shows cortical ribboning and basal ganglia hyperintensity (sensitivity 92%, specificity 94%). EEG reveals periodic sharp wave complexes (sensitivity ~65%, specificity ~86%). CSF RT-QuIC assay is the current gold standard (sensitivity ~90%, specificity ~99%).","management_principles":"No disease-modifying treatment exists. Management is supportive: anticonvulsants (clonazepam, valproate) for myoclonus; palliative care; psychosocial support. Experimental approaches (e.g., anti-prion compounds) remain investigational.","follow_up_guidelines":"Focus on symptom control, assess for aspiration risk, and provide multidisciplinary palliative support. Early involvement of neurology, palliative care, and social work is recommended.","clinical_pearls":"1) Rapidly progressive dementia with myoclonus is virtually pathognomonic for CJD. 2) MRI DWI hyperintensity in cortex and striatum is highly sensitive early. 3) RT-QuIC in CSF has replaced 14-3-3 protein testing. 4) There is no curative therapy\u2014swift palliative referral is essential. 5) Median survival <6 months underscores aggressive counseling for families.","references":"1. Zerr I et al. Neurology. 2020;94(20):e2185\u2013e2194. doi:10.1212/WNL.0000000000009413\n2. Orr\u00fa CD et al. Ann Neurol. 2017;81(2):274\u2013284. doi:10.1002/ana.24807\n3. Aguzzi A, Wuhrmann M. Trends Neurosci. 2018;41(4):216\u2013228. doi:10.1016/j.tins.2018.01.004\n4. Brown P. Prion. 2019;13(1):1\u201313. doi:10.1080/19336896.2019.1582777\n5. Kelley BP et al. Pract Neurol. 2019;19(4):380\u2013389. doi:10.1136/practneurol-2018-002191"},"ai_generated":true,"exam_year":"2018","exam_type":"Part One","source_file":"Part II 2018_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]